Celularity Inc. (CELU) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Celularity Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Celularity is a regenerative and cellular medicines company focused on aging-related and degenerative diseases. Its operations are divided into three segments: Cell Therapy (research and development of placental-derived allogeneic cell therapies), Degenerative Disease (commercial sale of biomaterials like Biovance 3L and Rebound), and BioBanking (collection and storage of umbilical cord blood and placental tissue).
Key Event: The company executed a 1-for-10 reverse stock split in February 2024. All share data in this summary reflects the post-split basis.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Net Revenues | $54.2 million | $22.8 million |
| Net Loss | $(57.9) million | $(196.3) million |
| Operating Loss | $(38.4) million | $(192.3) million |
| Cash and Cash Equivalents | $0.7 million | $0.2 million |
| Accumulated Deficit | $(899.7) million | $(841.8) million |
| Total Debt (Principal) | ~$43.3 million | ~$39.2 million |
| Net Cash Used in Operating Activities | $(6.4) million | $(38.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 138.1% to $54.2 million, driven primarily by a 168.7% increase in product sales (Biovance 3L and Rebound) and a 228.7% increase in license/royalty revenue from Rebound distribution.
- Profitability Improvement: Net loss decreased significantly from $196.3 million in 2023 to $57.9 million in 2024. This improvement was largely due to the absence of $220.1 million in non-cash impairment charges (Goodwill and IPR&D) recorded in 2023 and a $104.3 million gain from the change in fair value of contingent consideration liability in 2023 (vs. a $0.2 million gain in 2024).
- Expense Reduction: Research and Development (R&D) expenses decreased 42.9% to $17.4 million due to the discontinuation of certain clinical trials and workforce reductions. Selling, General, and Administrative (SG&A) expenses increased 16.0% to $58.6 million, primarily due to higher selling expenses associated with increased biomaterial sales.
- Asset Acquisition: In October 2024, the company acquired the Rebound product line from Sequence LifeScience for up to $5.5 million (cash and milestones).
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. As of the filing date, the company had only $0.7 million in cash and no secured additional capital to sustain operations for the next 12 months. The company has approximately $43.3 million in debt, most of which is due or due within one year and currently under forbearance agreements.
Outlook and Pipeline:
- Biomaterials: Plans to submit a 510(k) application for Celularity Tendon Wrap (CTW) in H2 2025, FUSE Bone Void Filler in H2 2026, and Celularity Placental Matrix (CPM) in H2 2027.
- Cell Therapy: Prioritizing PDA-002 for Diabetic Foot Ulcer (DFU) with an expected End of Phase 2 meeting with the FDA in H1 2025. PDA-001 for Crohn's Disease is under safety/efficacy assessment for potential Phase 3 progression.
Material Risks:
- Liquidity Crisis: Failure to secure additional financing could force the company to curtail operations, liquidate assets, or seek bankruptcy protection.
- Debt Maturities: Substantial indebtedness secured by all assets; failure to meet payment obligations could trigger default.
- Nasdaq Delisting: The company received notice of potential delisting due to failure to timely file the 10-K and unpaid fees. An appeal was filed in April 2025, but delisting remains a risk.
- Reimbursement Risk: CMS Local Coverage Determinations (LCDs) effective Jan 1, 2026, may deny coverage for amniotic tissue products, potentially harming the Degenerative Disease segment.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, including insufficient resources and failure to timely file reports.
Investor Verification Checklist
- Cash Runway: Verify the status of any new financing secured after the filing date to address the "substantial doubt" regarding going concern status.
- Debt Forbearance: Confirm the terms and status of forbearance agreements with major lenders (RWI, C.V. Starr, Yorkville) and whether any defaults have been triggered.
- Nasdaq Status: Monitor the outcome of the appeal regarding the 10-K filing delinquency and fee non-payment to assess delisting risk.
- Reimbursement Policy: Track the status of the CMS LCD effective Jan 1, 2026, and any potential suspensions or reversals that could impact the core biomaterials revenue stream.
- Internal Controls: Review subsequent filings for progress on remediating material weaknesses in financial reporting.